Geethakumari, Praveen Ramakrishnan
Ramasamy, Dheepthi Perumal
Dholaria, Bhagirathbhai
Berdeja, Jesús
Kansagra, Ankit http://orcid.org/0000-0001-6901-0782
Article History
Accepted: 27 April 2021
First Online: 5 June 2021
Declarations
:
: Praveen Ramakrishnan Geethakumari declares that he has no conflict of interest.Dheepthi Perumal Ramasamy declares that she has no conflict of interest.Bhagirathbhai Dholaria has received research funding from Takeda, Poseida Therapeutics, Janssen, and Angiocrine Bioscience, and has served on an advisory board for Jazz Pharmaceuticals.Jesús Berdeja has received research funding (paid in his name to his institution) from AbbVie, Amgen, Acetylon, bluebird bio, Bristol-Myers Squibb, Celgene, Celularity, Constellation Pharmaceuticals, CRISPR Therapeutics, Curis, EMD Serono, Genentech, Glenmark Pharmaceuticals, Ichnos Sciences, Janssen, Kesios Therapeutics, Eli Lilly, Novartis, Poseida Therapeutics, Sanofi, Takeda, Teva, and Vivolux; and has served as a consultant for Amgen, Bioclinica, bluebird bio, Bristol-Myers Squibb, Celgene, CRISPR Therapeutics, Janssen, Karyopharm Therapeutics, Kite Pharma, Legend Biotech, Prothena, Secura Bio, and Laboratoires Servier, with all compensation made payable to his institution.Ankit Kansagra has participated on advisory boards for Alnylam Pharmaceuticals, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides, Pharmacyclics, Pfizer, Takeda, and Sanofi.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
Free to read: This content has been made available to all.